+1 877 705 191424 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years - 59Years
All Genders
ID06794450

Comparing Recovery Speed of Half-Dose Sugammadex and Neostigmine for Muscle Relaxation Reversal in Adults Undergoing Laparoscopic Gallbladder Surgery

Led by Universitas Padjadjaran · Updated on 2025-01-28

60

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What this Trial Is About

Neuromuscular blocking agents like rocuronium are often used during surgeries such as laparoscopic cholecystectomy to help with intubation and muscle relaxation. This research compares two drugs, sugammadex and neostigmine, used to reverse the muscle relaxation after surgery. The goal is to see if half-dose sugammadex leads to faster recovery times than neostigmine, which is commonly used but has a slower and less predictable recovery. Participants will receive either sugammadex at 1 mgkg or neostigmine at 60 mcgkg combined with atropine after their surgery when moderate neuromuscular blockade is detected. Both groups will undergo the same anesthetic protocol, and muscle recovery will be monitored with a device called an acceleromyography monitor. Extubation will occur once the muscle function reaches a specific recovery level. During the study, patients muscle recovery times and possible side effects like bradycardia and hypotension will be closely observed. Monitoring includes checking the Train of Four Ratio to ensure safe extubation. The main outcome measured is the recovery time within one hour after reversal drug administration, with additional assessments for spontaneous recovery and safety within a few hours after surgery.

CONDITIONS

Brief Title

Recovery Times of Half Dose Sugammadex and Neostigmine for Rocuronium-induced Neuromuscular Blockade

Research Team

R

Rivan P Rivan Putra Afewa, M.D., M.D.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here